Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
about
Integrins in the Spotlight of CancerOncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpointsThe Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma CellsUnlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyCritical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific AntigensMicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMAIntranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma.Current challenges in designing GBM trials for immunotherapy.Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics.A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.Oncolytic virotherapy for urological cancers.The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.Healing after death: antitumor immunity induced by oncolytic adenoviral therapy.Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis.Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus.Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.Current state and future prospects of immunotherapy for glioma.Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors
P2860
Q28066805-C8292998-E33F-4861-BA68-CAF0E9028FBEQ28083515-E7EAE4B9-4690-4E01-9F02-F6C86A46EF43Q33633272-DF0FF019-E0F6-4343-A0D7-9AB9346A7260Q35636540-CBB9F341-D014-4933-BB82-649A20FE1A71Q35657822-751031C7-A302-4538-8166-AA2F0088C544Q35993889-20BBD96E-6BA7-44BD-9683-8EBB9AF22E56Q36086370-770B4A12-8AF8-4255-9CB2-CE876A37E843Q36549443-3A39CF8A-5B57-4715-B4D6-587F619B2EFBQ37274612-52C71555-FC21-4583-8D6A-CDD5BE544A1CQ38313826-9EF6873A-200F-4067-8934-FC4E9431E174Q38535624-C9F0FCDC-6F48-4948-9E77-4C820374D3DDQ38675900-8972CF99-A42F-4C08-9270-DF273A6887FFQ38702903-57AE3163-BBEF-478F-AD83-A5D6BC7A8509Q38715077-04873F7B-EE98-423D-A743-65CB94D96B47Q38718750-CF660E4C-923E-4CCC-B60E-3DC03A00614AQ38752688-1D4637D4-FD6A-4E19-B452-08F138482801Q38842126-6A812C86-205A-4985-AE10-211CC99833A1Q39294814-DCFF28C9-AABA-4E5E-82F8-82BDE81F2730Q42008858-0DD778F9-F4A0-431A-9881-8FA2ED584F2CQ47095296-511E32AC-E422-4056-BA17-17F523860AABQ47547236-F863C581-F11E-43C2-BEA1-2078EEAF4E1CQ47549079-FF3BD2D4-9629-4A1D-9376-050DCA4A96D0Q47557087-32FAD903-7E4E-4B8F-8BA6-8291BB8EE18CQ47827127-417ACF46-6509-412A-8BB2-358D0DC8B3FCQ50047493-0AAA31E1-7035-485D-A97F-19BD83B5B6E6Q50109459-5C47E596-2FF0-4A52-9FD1-F037500A4064Q52366335-64D305F6-C8AE-4521-97DE-18AA088D642AQ55509278-CEBBB97F-6BC0-4AE5-B6E7-D8F6B42DF684Q56892727-C9215766-3F0B-4EF5-84CB-306265EB3034
P2860
Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@ast
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@en
type
label
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@ast
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@en
prefLabel
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@ast
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@en
P2093
P2860
P1433
P1476
Delta-24-RGD oncolytic adenovi ...... n immunocompetent mouse model.
@en
P2093
Anne Kleijn
Candelaria Gomez-Manzano
Frederick F Lang
Hong Jiang
Juan Fueyo
Karen Clise-Dwyer
Kathryn E Ruisaard
Luis M Vence
Wai-Kwan Alfred Yung
P2860
P304
P356
10.1371/JOURNAL.PONE.0097407
P407
P577
2014-05-14T00:00:00Z